Clinical Cancer Research APC and Open Access: AACR's Translational Bridge at Moderate Cost

These two journals are often confused, and the distinction matters for where your paper fits:

Clinical Cancer Research occupies a specific niche: it wants work that connects laboratory findings to patient outcomes. The ideal paper includes both molecular data and clinical validation. A biomarker discovery study that shows prognostic value in a patient cohort fits perfectly. The same biomarker study without clinical validation belongs in Cancer Research or a molecular biology journal.

The journal is particularly strong in:

• Biomarker development and validation
• Correlative science from clinical trials (the molecular analyses that accompany phase I-III studies)
• Pharmacodynamic and pharmacokinetic studies of cancer therapeutics
• Imaging biomarkers and diagnostic development
• Immunotherapy response prediction and resistance mechanisms

Clinical Cancer Research is hybrid:

1. Subscription track ($0 APC, page charges apply): Published behind the AACR paywall. Institutional subscribers have access. You pay per-page charges.
2. Gold OA track ($4,200-$5,000): Immediate free access under a Creative Commons license. No page charges.

The subscriber base for AACR journals covers virtually every academic medical center and cancer research institution. Oncologists and translational researchers at these institutions can access Clinical Cancer Research through their library subscriptions. Behind the paywall, your paper still reaches the people who need to read it.

OA becomes more valuable for Clinical Cancer Research than for some basic science journals because of its clinical audience. Community oncologists, clinical trial coordinators at smaller sites, and researchers in lower-resource settings may not have institutional subscriptions. If your work has direct clinical practice implications, OA broadens its reach to these groups.

AACR membership provides meaningful publishing discounts:

• OA APC discount: ~$800 reduction for members across all AACR journals.
• Membership cost: $170-$340/year depending on career stage.
• Net savings: The discount on a single OA publication more than covers annual membership.

If you publish regularly in AACR journals, including Cancer Research, Clinical Cancer Research, Cancer Discovery, or Molecular Cancer Research, membership is an obvious investment. Many oncology researchers are already AACR members for conference access and networking, making the publishing discount an added bonus.

AACR provides the same waiver framework across all its journals:

• Geographic waivers: Full or partial APC waivers for authors from low-income and lower-middle-income countries per World Bank classification.
• Hardship waivers: Case-by-case requests considered for authors who can demonstrate financial need.
• Page charge waivers: Available when no grant or institutional funds exist. Requires corresponding author certification.

Clinical Cancer Research papers often come from large, funded clinical trials with substantial budgets. For these, APC funding is rarely an issue. The waiver system is more relevant for investigator-initiated translational studies from labs with tighter budgets, particularly at institutions outside major cancer centers.

AACR automatically deposits accepted manuscripts from NIH-funded research in PubMed Central, with public access after a 12-month embargo. This is a significant convenience. Many publishers leave the PMC deposit to authors, creating compliance gaps and administrative headaches. AACR handles it for you.

For Plan S compliance, select CC BY licensing at the production stage. Clinical Cancer Research supports both CC BY and CC BY-NC. Getting the license wrong requires a slow post-publication correction process.

Beyond the listed APC, watch for:

• Page charges on subscription track: A 14-page clinical manuscript costs ~$1,400 in page charges. Many authors are surprised by this invoice.
• Statistical review requests: Clinical Cancer Research may require statistical review or reanalysis during revision. If your institution charges for biostatistics consulting, budget for this.
• Clinical data formatting: The journal has specific requirements for CONSORT diagrams, waterfall plots, and swimmer plots. Professional figure preparation may cost $200-$500 if your team doesn't have the tools in-house.
• Tax: VAT or local taxes can add 15-25% to the APC in certain jurisdictions.
• Companion diagnostics data: Papers on biomarker-driven therapy often need supplementary validation datasets. Depositing large genomic datasets in GEO or EGA is free but time-consuming.

Clinical Cancer Research typically returns a first decision in 3-6 weeks. The full review-to-acceptance timeline runs 3-6 months for successful manuscripts, with one or two revision rounds being standard.

The desk-rejection rate is approximately 40-50%, similar to Cancer Research. Papers that are clearly outside the translational scope (pure basic biology or pure clinical reporting without molecular correlates) get redirected quickly. The editors want to see both a molecular story and clinical relevance.

For translational oncology researchers considering Clinical Cancer Research:

1. Join AACR if you haven't. The $170-$340 membership saves ~$800 on the OA APC. It pays for itself immediately.
2. Calculate page charges vs. OA APC. For manuscripts over 12 pages, the flat OA APC may be cheaper than subscription-track page charges.
3. Check institutional AACR deals. Your library may cover part or all of the APC through an institutional agreement.
4. NIH/NCI-funded? Use the free green route. AACR deposits in PMC automatically. You pay only page charges on the subscription track.
5. Choosing between CCR and JCO? If your paper has strong molecular biomarker data driving clinical conclusions, CCR is the natural home. If it's a clinical trial report, JCO or Annals of Oncology is more appropriate.

Translational manuscripts need to tell a coherent story from bench to bedside. The molecular data and the clinical data have to connect logically, and the framing needs to show why the translational finding matters for patient care. Run a free readiness scan to check whether your manuscript's translational narrative holds together before you submit.

For the latest fee schedule and author guidelines, visit the Clinical Cancer Research author information page.